Compare Alcon AG (ALC) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alcon AG vs Citius Pharmaceuticals Inc — how do they compare? Alcon AG trades at $72.55 (market cap $36.44B), while Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M). The key difference: Alcon AG is far larger — about 1821.1× Citius Pharmaceuticals Inc's market cap, and Alcon AG pays a 0.48% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ALC | CTXR | |
|---|---|---|
Market Cap | $36.44B | $20.01M |
Sector | Health | Health |
52-Week High | $90.12 | $1.82 |
52-Week Low | $62.02 | $0.48 |
Enterprise Value | $40.28B | $16.23M |
Dividend Yield | 0.48% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
